Some investors might love biotech stocks for their lottery ticket-like returns when a company strikes medical gold. A lottery ticket, however, costs only …
Anthera Pharmaceuticals Inc (NASDAQ:ANTH) announced the top line results of the SOLUTION clinical study in cystic fibrosis patients with exocrine pancreatic insufficiency (EPI). …
Anthera Pharmaceuticals Inc (NASDAQ:ANTH) announced that the Data Monitoring Committee (DMC) completed its pre-planned safety review of the SIMPLICITY clinical study of Sollpura …
Anthera Pharmaceuticals Inc (NASDAQ:ANTH) are having a rough day after the drug maker announced that the CHABLIS-SC1 clinical trial with blisibimod for the treatment …
Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) announced that the Data and Safety Monitoring Board (DSMB) completed its first pre-planned safety review of the Phase 3 SOLUTION …
Anthera Pharmaceuticals Inc (NASDAQ:ANTH) announced results from interim analysis of the Phase 2 BRIGHT-SC proof-of-concept study in 57 patients with biopsy-proven IgA Nephropathy. Additionally, …
Anthera Pharmaceuticals Inc (NASDAQ:ANTH) provided a business update and reported financial results for the first quarter ended March 31, 2016. Recent Developments and Business Highlights: …
Anthera Pharmaceuticals Inc (NASDAQ:ANTH) provided a business update and reported financial results for the third quarter ended September 30, 2015. Recent Developments and Business Highlights: …
Anthera Pharmaceuticals Inc (NASDAQ:ANTH) announced receipt of a termination notice from its development partner in Japan, Zenyaku, terminating the December 2014 Collaboration and License …
Anthera Pharmaceuticals Inc (NASDAQ:ANTH) announced financial results and an operational update for the second quarter ended June 30, 2015. Net loss for the quarter …